Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses

Citations Over TimeTop 10% of 2001 papers

Abstract

Studies of invasive fungal infections have been and remain difficult to implement. Randomized clinical trials of fungal infections are especially slow and expensive to perform because it is difficult to identify eligible patients in a timely fashion, to prove the presence of the fungal infection in an unequivocal fashion, and to evaluate outcome in a convincing fashion. Because of these challenges, licensing decisions for antifungal agents have to date depended heavily on historical control comparisons and secondary advantages of the new agent. Although the availability of newer and potentially more effective agents makes these approaches less desirable, the fundamental difficulties of trials of invasive fungal infections have not changed. Therefore, there is a need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, and this article summarizes the possible strategies in this area.

Related Papers

• → Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis(2015)18 cited
• → Invasive neonatal candidiasis: an overview(2003)42 cited
• → Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit(2010)18 cited
• → Critically ill patients at risk of invasive candidiasis: The “dilemma” of the best antifungal treatment strategy(2016)4 cited